Title:
PROPHYLACTIC OR THERAPEUTIC AGENT FOR PORPHYRIA
Document Type and Number:
WIPO Patent Application WO/2021/251450
Kind Code:
A1
Abstract:
A medicine for treating or preventing porphyria, which contains, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl\}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl\}piperidine-4-carboxylic acid or a pharmaceutically acceptable salt or cocrystal thereof. In the medicine for treating or preventing porphyria, the amount of 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl\}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl\}piperidine-4-carboxylic acid or a pharmaceutically acceptable salt or cocrystal thereof to be administered is 50 to 500 mg/day.
More Like This:
Inventors:
SUZUKI TSUYOSHI (JP)
KONDO MASAHIRO (JP)
TAKAHASHI FUMIHIRO (JP)
OGASAWARA AKIHITO (JP)
HYOUDOU KAZUMI (JP)
KONDO MASAHIRO (JP)
TAKAHASHI FUMIHIRO (JP)
OGASAWARA AKIHITO (JP)
HYOUDOU KAZUMI (JP)
Application Number:
PCT/JP2021/022036
Publication Date:
December 16, 2021
Filing Date:
June 10, 2021
Export Citation:
Assignee:
MITSUBISHI TANABE PHARMA CORP (JP)
International Classes:
A61K31/4545; A61P7/00; A61P17/00; A61P43/00; C07D401/14
Domestic Patent References:
| WO2015182723A1 | 2015-12-03 | |||
| WO2008025094A1 | 2008-03-06 | |||
| WO2015182723A1 | 2015-12-03 | |||
| WO2020138481A1 | 2020-07-02 |
Other References:
MINDER ELISABETH I., BARMAN-AKSOEZEN JASMIN, SCHNEIDER-YIN XIAOYE: "Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders", CLINICAL PHARMACOKINETICS, vol. 56, no. 8, 1 August 2017 (2017-08-01), NZ , pages 815 - 823, XP009541622, ISSN: 0312-5963, DOI: 10.1007/s40262-016-0501-5
Attorney, Agent or Firm:
IP FIRM SHUWA (JP)
Download PDF: